Equipment and Facilities are not designed to prevent the potential for contamination.
Inspection Record
Protein Sciences Corporation — FDA 483 Findings
Inspectors Christian Lynch · Richard L Bartlett · Matthew J GretkierewiczThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Written procedures designed to prevent microbiological contamination of drug substance are not established or are not followed.
Computerized systems used for the collection and analysis of quality data have not been validated.
Inadequate controls for inventory of critical starting materials in (6b)(4) used in the manufacture of Flublok Monovalent Drug Substance, which is used to manufacture Flublok recombinant influenza vaccine.
Flow of materials and equipment is not designed to prevent contamination.
The Quality Unit has failed to provide adequate oversight and ensure the implementation of effective corrective and preventive actions.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.